Oncology Drugs

Oncology Drugs Market by Indication (Bladder Cancer, Breast Cancer, Cervical Cancer), Drug Class (Chemotherapy, Hormonal Therapy, Immunotherapy), Route of Administration, Distribution, End-use - Global Forecast 2024-2030

360iResearch Analyst
SPEAK TO ANALYST? OR FACE-TO-FACE MEETING?
Want to know more about the oncology drugs market or any specific requirement? Ketan helps you find what you're looking for.
DOWNLOAD A FREE PDF
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[194 Pages Report] The Oncology Drugs Market size was estimated at USD 175.78 billion in 2023 and expected to reach USD 188.41 billion in 2024, at a CAGR 7.64% to reach USD 294.42 billion by 2030.

Oncology Drugs Market
To learn more about this report, request a free PDF copy

Oncology drugs are specialized pharmaceutical agents used in the treatment, diagnosis, and prevention of cancer. These drugs are pivotal in the management of malignancies as they target cancer cells with various mechanisms of action. Oncology drugs can be categorized into several types, including chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and others, each playing a unique role in oncology care. The surging prevalence of cancer worldwide, coupled with the increase in investments and government funding in the development of cancer drugs, propel the market growth. However, the cost of developing, testing, and securing regulatory approval for new drugs poses a significant challenge to the manufacturers. Furthermore, advancements in genomic sequencing technologies and biotechnology, along with the growing need for personalized medicines, create lucrative opportunities for market growth.

Oncology Drugs Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Drug Class: Growing significance of targeted therapy due to its precision and lower side effects

Chemotherapy involves the utilization of cytotoxic drugs to kill or hamper the growth of cancer cells. It is among the oldest forms of cancer treatment and can be used across various cancer types. Chemotherapy is often preferred for advanced cancers or cancers that have metastasized. It can be used as a sole treatment & in combination with other therapies. Hormonal therapy slows or prevents the growth of hormone-sensitive tumors by stopping the body's ability to produce hormones & by interfering with hormone action. This therapy is primarily used for breast and prostate cancers, which often grow in response to hormones. Immunotherapy boosts the body's natural defenses to combat cancer. It utilizes substances made by the body or in a laboratory to enhance and restore immune system function. Immunotherapy is preferred for cancers that have markers indicating they may respond to this treatment, such as melanoma, lung cancer, and kidney cancer. Targeted therapy targets the specific genes, proteins, or the tissue environment contributing to cancer growth and survival. This type of therapy stops the growth and prevalence of cancer cells while limiting damage to healthy cells. Targeted therapy is specifically used for cancers with genetic mutations that can be targeted with these drugs, such as certain types of lung, breast, and colorectal cancers.

End-use: Ongoing expansion of specialty cancer clinics accelerating the demand for oncology drugs

Home healthcare has seen a significant uptick in the demand for oncology drugs, attributed largely to the increasing preference for at-home treatments. Patients and families often find home healthcare options more comfortable, reducing the psychological stress associated with frequent hospital visits. Hospitals remain a critical endpoint for the administration of oncology drugs, especially for treatments that require advanced infrastructure and close medical supervision. They cater to a wide spectrum of cancers, often dealing with more severe cases that necessitate in-patient care. Specialty cancer clinics offer a middle ground between home healthcare and hospitals, providing specialized care in an outpatient setting. These clinics are pivotal for the ongoing treatment and monitoring of cancer patients, often facilitating access to the latest drugs and clinical trials.

Regional Insights

The American region represents a major market for oncology drugs, driven by high healthcare expenditure, robust research and development infrastructure, and a strong presence of leading pharmaceutical companies. Patents in novel drug delivery systems and targeted therapies highlight the country's innovation, while significant investment in cancer research & initiatives underscores a commitment to combating cancer. The European market is marked by a harmonized regulatory landscape that fosters a conducive environment for oncology drug development and approval. Differentiated by price sensitivity across member states, the market demands cost-effective oncology solutions alongside innovative therapies. The Middle East & Africa region presents a diverse market landscape, with Gulf Cooperation Council (GCC) countries showing high purchasing power for innovative oncology treatments, contrasted with Sub-Saharan Africa's focus on accessibility and affordability. The APAC region's oncology drugs market is rapidly expanding, fueled by a growing middle class, increased healthcare spending, and government initiatives aimed at healthcare reform. The APAC countries with significant players in oncology research and development are making strides in both the domestic and global oncology markets.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Oncology Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Oncology Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • FDA Approves XTANDI for High-Risk Prostate Cancer Management

    Astellas Pharma Inc. and Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for a new supplemental drug application of XTANDI (enzalutamide), making it an FDA-approved androgen receptor signaling inhibitor for treating nonmetastatic castration-sensitive prostate cancer (nmCSPC) with high-risk biochemical recurrence (BCR) at risk for metastasis. This approval, based on the Phase 3 EMBARK trial results, allows XTANDI to be administered with or without gonadotropin-releasing hormone (GnRH) analog therapy. [Published On: 2023-11-16]

  • Takeda's FRUZAQLA Receives FDA Approval for Metastatic Colorectal Cance

    The U.S. Food and Drug Administration (FDA) has recently granted approval for a novel lung cancer medication, Augtyro, developed by Bristol-Myers Squibb. This approval comes after the company's strategic acquisition of Turning Point Therapeutics for SUD 4.1 billion. [Published On: 2023-11-16]

  • FDA Approves Takeda's FRUZAQLA, a Novel Treatment for Metastatic Colorectal Cancer

    Takeda announced the FDA's approval of FRUZAQLA (fruquintinib), the selective inhibitor targeting all three VEGF receptor kinases, for the treatment of adults with metastatic colorectal cancer (mCRC) who have previously received standard chemotherapies and targeted therapies as appropriate. This novel oral, chemotherapy-free option, which was approved ahead of schedule under priority review, marks a significant advancement in treating mCRC regardless of biomarker status, offering a new avenue for survival benefits without compromising quality of life. [Published On: 2023-11-08]

Key Company Profiles

The report delves into recent significant developments in the Oncology Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agenus Inc., Amgen Inc., Aspen Pharmacare Holdings Limited, Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Debiopharm International SA, Eli Lilly and Company, EMD Serono, Inc. by Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Pfizer Inc., Puma Biotechnology, Inc., Shorla Pharma Ltd., Sun Pharmaceutical Industries Ltd., Sutro Biopharma, Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Oncology Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication
    • Bladder Cancer
    • Breast Cancer
    • Cervical Cancer
    • Colorectal Cancer
    • Esophagus Cancer
    • Kidney Cancer
    • Liver Cancer
    • Lung Cancer
    • Prostate Cancer
    • Stomach Cancer
  • Drug Class
    • Chemotherapy
    • Hormonal Therapy
    • Immunotherapy
    • Targeted Therapy
  • Route of Administration
    • Intravenous
    • Oral
    • Topical
  • Distribution
    • Offline Pharmacies
      • Hospital Pharmacies
      • Retail Pharmacies
    • Online Pharmacies
  • End-use
    • Home Healthcare
    • Hospitals
    • Specialty Cancer Clinics

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Oncology Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Oncology Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Oncology Drugs Market?
  4. What is the market share of the leading vendors in the Oncology Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Oncology Drugs Market?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Oncology Drugs Market, by Indication
  7. Oncology Drugs Market, by Drug Class
  8. Oncology Drugs Market, by Route of Administration
  9. Oncology Drugs Market, by Distribution
  10. Oncology Drugs Market, by End-use
  11. Americas Oncology Drugs Market
  12. Asia-Pacific Oncology Drugs Market
  13. Europe, Middle East & Africa Oncology Drugs Market
  14. Competitive Landscape
  15. Competitive Portfolio
  16. List of Figures [Total: 26]
  17. List of Tables [Total: 568]
  18. List of Companies Mentioned [Total: 24]
Frequently Asked Questions
  1. How big is the Oncology Drugs Market?
    Ans. The Global Oncology Drugs Market size was estimated at USD 175.78 billion in 2023 and expected to reach USD 188.41 billion in 2024.
  2. What is the Oncology Drugs Market growth?
    Ans. The Global Oncology Drugs Market to grow USD 294.42 billion by 2030, at a CAGR of 7.64%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.